The latest updates you cannot miss.
IBA recently signed a contract with IAEA for the installation of a Cyclone® KEY in Benin, West Africa
By signing a contract with International Atomic Energy Agency (IAEA) for the installation of a Cyclone® KEY, our compact cyclotron, in Benin, West Africa, as part of the Rays of Hope initiative, we confirm the potential of IBA's Cyclone® KEY to make PET imaging more accessible globally.
It is part of the projects included in the Rays of Hope initiative which provides radiation support, whether in infrastructure, safety legislation, quality control, guidance, training or essential equipment to countries without radiotherapy or equitable access. Rays of Hope focuses on prioritizing a limited number of high-impact, cost-effective and sustainable interventions in line with national needs and commitment.
With the Cyclone® KEY, we enable small and medium-sized hospitals to produce their own radiopharmaceutical products in-house, while providing widespread global access to diagnostic solutions in oncology, neurology and cardiology, especially in regions across the world with limited access to this diagnostic technology.
Major milestone reached with the sale of the 100th Cyclone® KIUBE cyclotron!
We have reached the notable milestone of the sale of the 100th Cyclone® KIUBE cyclotron earlier this year.
It demonstrates the world leading position of this machine on the mid energy cyclotron market.
Let's see through the eyes of our long-term users of IBA cyclotrons [page to create]
During the last few months we had the pleasure to finalize several installations of Cyclone® KIUBE!
IBA Cyclone® KIUBE 300 has landed, bringing a new era of PET radiopharmaceuticals to Jakarta in Indonesia!
This first high-capacity GMP PET Pharmacy, powered by the robust Cyclone® KIUBE 300 is a game-changer for a better access to PET-CT scanning across Indonesia. Congratulations to PT Kardia Farma Solusindo team at for their hard work and collaboration.
Congratulations to AMS Pharmaceutical, in Jinan for the rigging of a new Cyclone® KIUBE in China!
It is a major milestone for AMS Pharmaceutical that will be able to increase its radioisotopes' production with this new Cyclone® KIUBE 150 equipped with 2 liquid targets for 18F, 1 Nirta® solid Plus target with custom energy, 1 HighMOR® module for advanced production of 124I, and much more!
The Cyclone® KIUBE and its self-shielding were rigged at the Sart-Tilman hospital, CHU de Liège in Belgium.
This new Cyclone® KIUBE, equipped with 2 liquid targets for 18F, 1 gas target for 11C-CO2 and 1 gas target for 15O, represents a significant milestone for the nuclear medicine service of Sart-Tilman, managed by Professor Roland Hustinx, to increase their own radioisotopes production, including 18F and 68Ga. Congratulations to the CHU Liège team on this major achievement!
Contract signed for Cyclone® IKON in Asia
We are pleased to announce that IBA signed a contract for a Cyclone® IKON in Asia in the first quarter of 2024.
iThemba LABS ready to start production of Strontium-82 and Germanium-68 using IBA Cyclone® 70
The Cyclone® 70 system installed at the iThemba LABS in Cape Town, one of the research facilities of the National Research Foundation of South Africa, has been fully commissioned enabling iThemba LABS to start transferring the production of radioisotopes from their existing accelerator to the new Cyclone® 70 system.
Neuraceq®, amyloid-PET diagnostic in Alzheimer's Disease now reimbursed in Japan
Neuraceq®, produced with Synthera®+, our fully automated synthesizer optimized to produce florbetaben 18F, is the first amyloid PET diagnostic tool reimbursed in Japan. It detects amyloid plaques in the brain, which are characteristic markers of Alzheimer's disease and other forms of cognitive impairment.
Now the question is whether the approval of novel AD drugs in Europe and the reimbursement of the first amyloid PET diagnostic tool in Japan will unleash the use of amyloid PET imaging?
Discover more about it with the expertise of Prof Barthel (DE) and Dr Fujibayashi (JPN)
Synthera®+ is now up and running at CMI, set to produce Neuraceq® (florbetaben 18F) amyloid PET diagnostic.
Congratulations to CMI and Life Molecular Imaging teams for their tireless efforts in making this project a success!
Synthera®+ platform has exceeded 5.500 runs on the Universidade de Coimbra site since its installation!
What a remarkable performance and proof of the reliability of IBA Synthera®+ platform! Consistent production and maximum uptime demonstrate its superior reliability, ensuring optimized radiopharmaceuticals production as 68Ga produced on liquid target with 3 daily runs!.
Congratulations to the University of Chicago Medicine team on the development of a simplified protocol for the automated production of 2-[18F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ([18F]nifene) on an IBA Synthera® module.
The α4β2 nicotinic acetylcholine receptor is associated with neurological disorders including Alzheimer's and Parkinson's. Scientists are refining imaging techniques using [18F]nifene, a faster-acting PET radiotracer, to better understand and visualize this receptor in these conditions.